Rigel Pharmaceuticals, Inc.NASDAQ: RIGL

Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results

· Issued by Rigel Pharmaceuticals, Inc. via PR Newswire

Summary by 6ix AI

Rigel Pharmaceuticals, Inc., a biotechnology company focused on therapies for blood disorders and cancer, will report its second quarter 2026 financial results after market close on Tuesday, August 4, 2026.

Key details

  • Senior management will hold a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the results and give a business update.
  • The call can be reached by dialing 877-407-3088 (domestic) or 201-389-0927 (international); the webcast and slides will be on the Investor Relations section of www.rigel.com, with a replay available for 90 days.

6ix AI wrote this summary from the release below and checked it against the release.

SOUTH SAN FRANCISCO, Calif., July 28, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its second quarter 2026 financial results after market close on Tuesday, August 4, 2026. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business.

Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and will be accessible from the Investor Relations section of the company's website at www.rigel.com. The webcast will be archived and available for replay for 90 days after the call via the Rigel website.

About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com.

Contact for Investors & Media:
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
[email protected]

Media:
David Rosen
Argot Partners
Phone: 646.461.6387
Email: [email protected]

Rigel Pharmaceuticals Logo

View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financial-results-302835770.html

SOURCE Rigel Pharmaceuticals, Inc.

View original source (PR Newswire)Rigel Pharmaceuticals, Inc. on 6ix

Story so far

Earlier from Rigel Pharmaceuticals

Later from Rigel Pharmaceuticals

All Rigel Pharmaceuticals news releases